Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Respiratory Aspiration 1Lymphoma, Follicular 1COVID-19 1

Interventions

Rituximab 48Cyclophosphamide 27Lenalidomide 23Peripheral Blood Stem Cell Transplantation 16obinutuzumab 10fludarabine phosphate 10Filgrastim 10Etoposide 10Bendamustine Hydrochloride 10Vincristine 8Prednisone 8Doxorubicin 8fludarabine 7Radiotherapy 7Mycophenolic Acid 7Melphalan 7Cyclosporine 7Bortezomib 7venetoclax 6tazemetostat 6ibritumomab tiuxetan 6Whole-Body Irradiation 6Gemcitabine 6pembrolizumab 5ibrutinib 5Ifosfamide 5Granulocyte Colony-Stimulating Factor 5CT-P10 5veltuzumab 4Methotrexate 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Lymphoma, Follicular × IBIO123 × Clear all
NCT05303376 2023-09-13

Phase 1&2 Study to Evaluate the Safety & Efficacy of Inhaled IBIO123 in Severe COVID-19 Illness

Immune Biosolutions Inc

Phase 1/2 Completed
123 enrolled
Lymphoid

COVID-19, Lymphoma, Follicular, Respiratory Aspiration

Data powered by HemOnc (CC BY 4.0) Colophon âš¡